Usual Adult Dose for Nausea/Vomiting - Postoperative

Prophylaxis: 5 mg given IV infusion over 1 to 2 minutes ONCE
Treatment: 10 mg given via IV injection over 1 to 2 minutes) ONCE

Comments:

• Preventative doses should be given at the induction of anesthesia.
• Treatment doses should be given after surgical procedures.
• IV lines may be flushed before or after administration with compatible fluids.

• Alone or in combination with an antiemetic of a different class for the prevention of PONV
• Treatment of postoperative nausea and vomiting (PONV) in patients who received antiemetic prophylaxis with an agent of a different class OR in those who did not receive prophylaxis

Renal Dose Adjustments

Mild to moderate renal dysfunction (estimated glomerular filtration rate [eGFR] 30 mL/min/1.73 m3 and greater): No adjustment recommended.
Severe renal dysfunction (eGFR less than 30 mL/min/1.73 m2): Not recommended.

Liver Dose Adjustments

Data not available

Precautions

CONTRAINDICATIONS:

• Hypersensitivity to the active component or to any of the ingredients

Dialysis

Data not available

Other Comments

Administration advice:

• Oral formulations should be taken after meals.
• Oral solutions should be consumed with a liquid not containing alcohol.
• IV formulations should be inspected thoroughly for discoloration and particulate matter prior to administration; solutions that are discolored or with particulate matter should be discarded.

• IV: Protect from light and use within 12 hours of removing from protective carton.
• Oral solution: Store below 25; any unused solution should be discarded after 2 months of opening.
• Tablets: Protect from moisture.

• IV: Dilution is not required.

• Compatible: 5% dextrose, 0.9% sodium chloride, and water for injection

• Some oral solution and tablet formulations are not interchangeable. The manufacturer product information should be consulted.

• CARDIOVASCULAR: ECG monitoring in patients receiving IV formulations with/at risk of QT prolongation
• ENDOCRINE: Serum prolactin levels in patients receiving prolonged treatment
• HEMATOLOGIC: Hematologic investigations in patients receiving prolonged treatment with evidence/suspected of having blood dyscrasia
• HEPATIC: Signs/symptoms of liver toxicity should be immediately reported, especially in patients receiving prolonged treatment

• Inform patients that this drug may cause blurred vision, decreased reaction time, and/or somnolence, and they should avoid driving or operating machinery if these side effects occur.
• Advise patients to speak to their healthcare provider if they become pregnant, intend to become pregnant, or are breastfeeding.